quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 13, 2026

Aduro signe une lettre d’intention pour l’achat d’huile Hydrochemolytic™ avec un programme de validation Pilot-to-FOAK (du site pilote à l’usine pionnière)

View original at globenewswire.com
Aduro signe une lettre d’intention pour l’achat d’huile Hydrochemolytic™ avec un programme de validation Pilot-to-FOAK (du site pilote à l’usine pionnière) LONDON, Ontario, 13 mars 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global chemical recycling market was valued at approximately 15.5 billion USD in 2024 and is expected to grow at a compound annual growth rate of approximately 9.8% through 2030.

    60% confidence
  • Hydrochemolytic oil is characterized by low olefin and heteroatom concentrations, properties that should enable processing with minimal additional steps compared to many conventional chemical recycling products.

    60% confidence
  • The LOI brings together two important elements: technical validation and a preliminary commercial framework. The pilot phase allows establishing product specifications and determining commercial value with a global trading partner, while the purchase commitment for the first FOAK production batch establishes the first commercial product pathway.

    60% confidence
  • Obtaining a structured purchase commitment at the FOAK phase demonstrates efforts to align technology validation and market demand. Circular feedstocks must meet the requirements of existing petrochemical infrastructure while satisfying regulatory and certification standards. This LOI directly connects pilot validation work to commercial production and marks an important milestone in the milestone-driven commercialization process.

    60% confidence
  • Pilot-scale steam cracking tests previously conducted with an industrial partner demonstrated stable cracking performance under pilot operating conditions.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Aduro signe une lettre d’intention pour l’achat d’huile Hydrochemolytic™ avec un programme de validation Pilot-to-FOAK (du site pilote à l’usine pionnière) — Source | Via News | pt.VIA.NEWS